Table 2. Changes in parameters of obese patients who received 15 mg or 30 mg phentermine for 6 months.
| Parameter | 3 months | 6 months | ||
|---|---|---|---|---|
| Phentermine 15 mg | Phentermine 30 mg | Phentermine 15 mg | Phentermine 30 mg | |
| ∆ Weight (kg) | –4.5 ± 0.18* | –5.8 ± 0.18*,** | –6.9 ± 0.4* | –8.4 ± 0.4*,** |
| Lost body weight (≥ 5%)# | 184 (49.9)* | 302 (62.3)*,** | 97 (76.7)* | 152 (82.2)* |
| Lost body weight (≥ 10%)# | 59 (16.0)* | 117 (24.1)*,** | 55 (43.7)* | 76 (41.1)* |
| ∆ BMI (kg/m2) | –1.9 ± 0.07* | –2.3 ± 0.07*,** | –2.9 ± 0.2* | –3.3 ± 0.2* |
| ∆ Waist circumference (cm) | –5.1 ± 0.3* | –6.2 ± 0.3*,** | –8.5 ± 0.6* | –8.2 ± 0.6* |
| ∆ Hip circumference (cm) | –3.6 ± 0.3* | –4.7 ± 0.2*,** | –5.8 ± 0.5* | –6.7 ± 0.4* |
| ∆ Body fat (%) | –2.3 ± 0.3* | –2.8 ± 0.3* | –3.3 ± 0.3* | –3.9 ± 0.3* |
| ∆ Visceral fat (%) | –0.6 ± 0.1* | –1 ± 0.07*,** | –0.9 ± 0.2* | –1.3 ± 0.1* |
| ∆ Glucose (mg/dL) | –14.4 ± 2.2* | –9.0 ± 2.8*,** | –9.7 ± 3.5* | –3.5 ± 2.2*,** |
| ∆ SBP (mmHg) | –2.9 ± 0.7* | –2.1 ± 0.6* | –5.4 ± 1.2* | –3.2 ± 1.0* |
| ∆ DPB (mmHg) | –2.0 ± 0.5* | –1.6 ± 0.4* | –3.4 ± 0.9* | –4.0 ± 0.9* |
| ∆ Heart rate (bpm) | –3.20 ± 0.93* | 0.43 ± 0.97** | –0.98 ± 1.82 | –2.38 ± 1.38 |
Data expressed as the mean (SEM) or #number of patients (%). *Significantly different with respect to baseline value, and **significantly different with respect to 15 mg phentermine (p < 0.05), as determined by #χ2 or analysis of variance, followed by Games-Howell’s test. BMI = body mass index; SBP = systolic blood pressure; DPB = diastolic blood pressure.